logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Selpercatinib Trial - Quick Facts

Eli Lilly And Co. (LLY) reported positive data from the LIBRETTO-001 trial intended to support the registration of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer. The study showed 68 percent objective response rate and sustained durability. Selpercatinib was well-tolerated in the study.

Josh Bilenker, interim senior vice president of oncology research and early phase development at Lilly, said: "We look forward to submitting the NDA later this year, and should selpercatinib receive regulatory approval, patients with RET fusion-positive NSCLC will finally have their first genomically-guided medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Libra Association, formed by major financial partners of Facebook's Libra cryptocurrency project, formalized the association at the inaugural Libra Council meeting of the members at its headquarters in Geneva, Switzerland. The current 21 member organizations formally signed onto the Libra Association charter, elected the Board of Directors, and appointed the executive team. Department store chain Kohl's Corp. has unveiled its Kohl's Cares holiday collection that includes the Disney Frozen 2 and Holiday Character bundles. The company's philanthropic program, Kohl's Cares, sells children's books as well as toys and donates the entire profit to charitable initiatives nationwide. Children's Place Inc. (PLCE) said that it will relaunch the Gymboree brand in the U.S. and Canada in early 2020. The brand will be relaunched in Gymboree website, and in shop-in-shop locations in more than 200 Children's Place stores in the U.S. and Canada.
Follow RTT
>